| human | Q5 |
| P106 | occupation | researcher | Q1650915 |
| Q42257952 | Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia |
| Q37273161 | Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months |
| Q33914289 | Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia |
| Q34964597 | Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia |
| Q35688721 | Characteristics of Sweet Syndrome in patients with acute myeloid leukemia |
| Q33949752 | Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia |
| Q99207639 | Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia |
| Q35995232 | EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience |
| Q37095355 | Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities |
| Q33968372 | Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy |
| Q33840247 | Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) |
| Q91473468 | Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes |
| Q28689231 | Measuring the symptom burden associated with the treatment of chronic myeloid leukemia |
| Q34086334 | Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse |
| Q91638072 | Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable |
| Q38123196 | Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia |
| Q37178948 | Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents |
| Q36907832 | Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation |
| Q35224437 | Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome |
| Q90558077 | Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R |
| Q42796621 | Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis |
| Q34205736 | Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics |
| Q96614801 | Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts |
| Q91011066 | TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups |
| Q42587106 | The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia |
| Q42958720 | The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia |
| Q42397477 | The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure |
| Q33854868 | Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options |
| Q48122085 | Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care |
Search more.